Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EGFR | P00533 | 7/20 | 0.56 |
| ▸ | KDR | P35968 | 4/20 | 0.56 |
| ▸ | KDM1A | O60341 | 1/20 | 0.52 |
| ▸ | RCOR1 | Q9UKL0 | 1/20 | 0.52 |
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.51 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.51 |
| ▸ | HTT | P42858 | 1/20 | 0.50 |
| ▸ | LMNA | P02545 | 1/20 | 0.49 |
| ▸ | GLA | P06280 | 1/20 | 0.49 |
| ▸ | POLB | P06746 | 1/20 | 0.49 |
| ▸ | GAA | P10253 | 1/20 | 0.49 |
| ▸ | SMARCA2 | P51531 | 1/20 | 0.49 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.49 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.47 |
| ▸ | CSF1R | P07333 | 2/20 | 0.46 |
| ▸ | EHMT2 | Q96KQ7 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30455210 | 1.00 | EGFR (0.56) | EGFRKDRKDM1ARCOR1SMN1; SMN2 | |
| SCHEMBL14952546 | 0.87 | TLR7 (0.49) | EGFRKDRKDM1ARCOR1SMN1; SMN2 | |
| SCHEMBL18941740 | 0.83 | TLR9 (0.54) | EGFRKDRKDM1ARCOR1CSF1R | |
| SCHEMBL3122320 | 0.80 | EGFR (0.64) | EGFRKDRCSF1R | |
| SCHEMBL3112154 | 0.80 | EGFR (0.68) | EGFRKDRCSF1R | |
| SCHEMBL7268508 | 0.79 | EGFR (0.52) | EGFRKDRKDM1ARCOR1SMN1; SMN2 | |
| SCHEMBL29532044 | 0.79 | SMN1; SMN2 (0.56) | EGFRKDRSMN1; SMN2ALDH1A1HTT | |
| SCHEMBL294809 | 0.79 | SMN1; SMN2 (0.56) | EGFRKDRSMN1; SMN2ALDH1A1HTT | |
| SCHEMBL938619 | 0.78 | EGFR (0.55) | EGFRKDRKDM1AALDH1A1HTT | |
| SCHEMBL16140738 | 0.77 | ALDH1A1 (0.40) | EGFRKDRKDM1ASMN1; SMN2ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250051290-A1 | NOVEL COMPOUND FOR IMPROVING SLEEP OR USE THEREOF | UNIV AJOU IND ACADEMIC COOP FOUND (KR) | 2025-02-13 | — | — | US | disclosed |
| WO-2023121429-A1 | NOVEL COMPOUND FOR IMPROVING SLEEP OR USE THEREOF | 아주대학교산학협력단 | 2023-06-29 | — | — | WO | disclosed |
| EP-2346848-B1 | QUINAZOLINE DERIVATIVES AS NK3 RECEPTOR ANTAGONISTS | HOFFMANN LA ROCHE (CH) | 2013-02-27 | — | — | EP | disclosed |
| US-8318749-B2 | Quinazoline derivatives as NK3 receptor antagonists | HOFFMANN-LA ROCHE INC. (US) | 2012-11-27 | — | — | US | disclosed |
| US-20100125078-A1 | QUINAZOLINE DERIVATIVES AS NK3 RECEPTOR ANTAGONISTS | HOFFMANN-LA ROCHE, INC. | 2010-05-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100125078-A1 | QUINAZOLINE DERIVATIVES AS NK3 RECEPTOR ANTAGONISTS | SLC6A3, OPRK1, HTR3A | EGFR 2117/4885KDR 867/4885KDM1A 3480/4885 |
| US-20250051290-A1 | NOVEL COMPOUND FOR IMPROVING SLEEP OR USE THEREOF | ADORA2A, HCRTR1, ADORA1 | EGFR 4773/4885KDR 4622/4885KDM1A 743/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.